Backed by market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, wider supply chain intelligence, emerging startup coverage, and detailed product-level insights, The Business Research Company’s 2026 market reports are designed to offer research that is more actionable and strategically valuable than ever.
Gene Therapy Market Revenue Growth On Track For A 13.5% CAGR Through 2030
The gene therapy market size has seen substantial growth in recent years. It is projected to increase from $16.36 billion in 2025 to $21.46 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 31.2%. This growth in the past can be ascribed to the increasing occurrence of genetic disorders, advancements in viral vector technology, greater research and development investments in gene therapy, favorable government policies, and an uplifted awareness of rare diseases.
The gene therapy market size is anticipated to undergo significant expansion in the next few years, with projections indicating a rise to $35.61 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 13.5%. This growth throughout the forecast period is primarily fueled by factors such as the broadening scope of personalized medicine, the advent of CRISPR and gene editing therapies, increased public and private sector funding, the integration of artificial intelligence into gene therapy research, and an uptick in collaborative international clinical trials. Key developments expected during this period encompass the progression of personalized gene therapy, widespread acceptance of CRISPR and gene editing technologies, the expansion of regulatory and ethical frameworks, innovation in advanced viral and non-viral vectors, and enhanced collaborative research and clinical trials.
Get A Free Sample Report With In-Depth Market Insights:
Gene Therapy Market Growth Drivers: What’s Behind The Acceleration?
Increased financial commitment in the healthcare sector is projected to fuel the expansion of the gene therapy market in the future. This type of investment involves dedicating capital to entities involved in delivering medical care, producing medical devices or pharmaceuticals, offering health coverage, or generally participating in the healthcare domain. Such capital injection is crucial for the gene therapy industry because numerous pharmaceutical firms are investing to strengthen their patent holdings and forge profitable collaborations. Furthermore, strategic funding facilitates the creation of innovative and advanced gene therapy solutions. A notable example is provided by the American Medical Association, a US-based professional organization, which reported in April 2025 that U.S. health spending in 2023 rose by 7.5% to reach $4.9 trillion, equivalent to $14,570 per capita, a growth rate that exceeded the 4.6% increase observed in 2022. Consequently, the increasing financial outlay within the healthcare industry is indeed stimulating the expansion of the gene therapy market.
Gene Therapy Market Segment Breakdown: Which Categories Lead On Revenue?
The gene therapy market covered in this report is segmented –
1) By Gene Therapy Type: Germline Therapy, Somatic Cell Therapy
2) By Vector: Viral Vector, Non-Viral Vector
3) By Application: Oncology, Orphan Disease, Knee Osteoarthritis, Neurological Disorders
4) By End Users: Biopharmaceutical Companies, Research Institutes, Other End Users
Subsegments:
1) By Germline Therapy: Inherited Disease Treatment, Genetic Modification Of Embryos, Gene Editing Techniques, Ethical And Regulatory Considerations
2) By Somatic Cell Therapy: Cancer Gene Therapy, Monogenic Disorder Treatment, Gene Replacement Therapy, RNA-Based Therapies, Gene Editing Techniques
Gene Therapy Market Trends: What’s Defining The Industry’s Next Phase?
Companies operating in the gene therapy market are concentrating on developing advanced products, such as adeno-associated virus (AAV) vectors, to enhance the precision and efficacy of gene delivery for treating various genetic disorders. An adeno-associated virus (AAV) vector is a common tool utilized in gene therapy to deliver genetic material into cells. For instance, in April 2024, Pfizer Inc., a US-based global biopharmaceutical company, obtained approval from the Food and Drug Administration (FDA), a US-based federal agency responsible for protecting public health, for BEQVEZ (fidanacogene elaparvovec-dzkt). BEQVEZ (fidanacogene elaparvovec-dzkt) is a gene therapy intended for treating adults with moderate to severe hemophilia B, which is a genetic bleeding disorder. This condition is marked by a deficiency in clotting factor IX (FIX), leading to potential excessive bleeding. It leverages an adeno-associated virus (AAV) vector to deliver a functional copy of the FIX gene directly into liver cells, thereby enabling the natural production of this crucial clotting factor.
Gene Therapy Market Leading Players And Competitive Positioning
Major companies operating in the gene therapy market are UniQure NV, REGENXBIO Inc., Bristol-Myers Squibb, BioMarin Pharmaceuticals Inc., Jazz Pharmaceuticals Inc., Biocon, EdiGene Inc, Takeda Pharmaceutical, Daiichi Sankyo Company, Mitsubishi Tanabe Pharma, Merck, Lonza, Pfizer, Cellular Biomedicine Group, GenScript, Albumedix Ltd, Catalent, Freeline Therapeutics, DiNAQOR AG, Vivet Therapeutics, Allergan, Amgen, Biocad, Celgene Corporation, Johnson & Johnson, Eli Lilly and Company, AstraZeneca, Bayer AG, Juno Therapeutics, Allogene Therapeutics, Bluebird Bio, Regen BioPharma, Bellicum, BrainStorm Cell Therapeutics, Pluristem, Sanofi
View The Full Gene Therapy Market Report:
Gene Therapy Market Leading Geography: Which Region Contributes The Most Revenue?
North America was the largest region in the gene therapy market in 2025. The regions covered in the gene therapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
